Global Oligonucleotide Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Oligonucleotide Therapeutics market size was valued at US$ 8013 million in 2025 and is forecast to a readjusted size of US$ 10250 million by 2032 with a CAGR of 3.6% during review period.
Oligonucleotide therapeutics are a class of precision medicines composed of short DNA or RNA sequences designed to specifically target and modulate the expression of genes involved in disease processes. These therapies can act by silencing, inhibiting, or correcting genetic abnormalities at the molecular level, offering a highly targeted approach to treat various conditions such as genetic disorders, cancers, and viral infections. Oligonucleotide therapeutics include antisense oligonucleotides, small interfering RNA (siRNA), and aptamers, and they represent a promising area of drug development due to their ability to address previously untreatable diseases.
Key driver of the oligonucleotide therapeutics market is the growing prevalence of genetic and rare diseases that require precise and targeted treatment options. Advances in genomics and personalized medicine have fueled interest in oligonucleotide therapies, which can directly modulate gene expression and offer solutions for conditions that were previously difficult to treat. The success of approved oligonucleotide drugs, such as antisense oligonucleotides and siRNA therapies, has increased confidence in this field, leading to more investments and research in developing novel treatments for a wide range of diseases, including cancers and neurological disorders.
One significant challenge in the oligonucleotide therapeutics market is the complexity of delivering these molecules effectively to target cells or tissues. Oligonucleotides are large, negatively charged molecules that face hurdles in stability, bioavailability, and efficient cellular uptake. Developing delivery systems that can ensure targeted and sustained delivery while minimizing immune responses or off-target effects remains a critical challenge. Additionally, the high costs associated with research, development, and manufacturing of oligonucleotide-based drugs pose financial challenges, limiting accessibility and widespread adoption, especially in resource-constrained healthcare settings.
Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023. Following Europe, North Americas is the second largest consumption place with the consumption market share of 34.9%. The global key companies of oligonucleotide therapeutics include Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2023, the global top five players had a share approximately 97.87% in terms of revenue.
This report is a detailed and comprehensive analysis for global Oligonucleotide Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Oligonucleotide Therapeutics market size and forecasts, in consumption value ($ Million), 2021-2032
Global Oligonucleotide Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Oligonucleotide Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Oligonucleotide Therapeutics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oligonucleotide Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Oligonucleotide Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Oligonucleotide Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Oligonucleotide Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oligonucleotide Therapeutics, with revenue, gross margin, and global market share of Oligonucleotide Therapeutics from 2021 to 2026.
Chapter 3, the Oligonucleotide Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Oligonucleotide Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oligonucleotide Therapeutics.
Chapter 13, to describe Oligonucleotide Therapeutics research findings and conclusion.
Oligonucleotide therapeutics are a class of precision medicines composed of short DNA or RNA sequences designed to specifically target and modulate the expression of genes involved in disease processes. These therapies can act by silencing, inhibiting, or correcting genetic abnormalities at the molecular level, offering a highly targeted approach to treat various conditions such as genetic disorders, cancers, and viral infections. Oligonucleotide therapeutics include antisense oligonucleotides, small interfering RNA (siRNA), and aptamers, and they represent a promising area of drug development due to their ability to address previously untreatable diseases.
Key driver of the oligonucleotide therapeutics market is the growing prevalence of genetic and rare diseases that require precise and targeted treatment options. Advances in genomics and personalized medicine have fueled interest in oligonucleotide therapies, which can directly modulate gene expression and offer solutions for conditions that were previously difficult to treat. The success of approved oligonucleotide drugs, such as antisense oligonucleotides and siRNA therapies, has increased confidence in this field, leading to more investments and research in developing novel treatments for a wide range of diseases, including cancers and neurological disorders.
One significant challenge in the oligonucleotide therapeutics market is the complexity of delivering these molecules effectively to target cells or tissues. Oligonucleotides are large, negatively charged molecules that face hurdles in stability, bioavailability, and efficient cellular uptake. Developing delivery systems that can ensure targeted and sustained delivery while minimizing immune responses or off-target effects remains a critical challenge. Additionally, the high costs associated with research, development, and manufacturing of oligonucleotide-based drugs pose financial challenges, limiting accessibility and widespread adoption, especially in resource-constrained healthcare settings.
Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023. Following Europe, North Americas is the second largest consumption place with the consumption market share of 34.9%. The global key companies of oligonucleotide therapeutics include Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2023, the global top five players had a share approximately 97.87% in terms of revenue.
This report is a detailed and comprehensive analysis for global Oligonucleotide Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Oligonucleotide Therapeutics market size and forecasts, in consumption value ($ Million), 2021-2032
Global Oligonucleotide Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Oligonucleotide Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Oligonucleotide Therapeutics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oligonucleotide Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Oligonucleotide Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Oligonucleotide Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Antisense Oligonucleotides (ASO)
- siRNA
- mRNA
- Neuromuscular Diseases
- hATTR
- COVID-19
- Other
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Alnylam
- Biogen
- Nippon Shinyaku
- Sobi
- Novartis
- BioNTech
- Pfizer
- Moderna Therapeutics
- Jazz Pharmaceuticals
- CureVac
- Regulus Therapeutics
- ProQR
- Secarna
- MiNA Therapeutics
- Sylentis
- Arrowhead
- Silence Therapeutics
- Dicerna
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Oligonucleotide Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oligonucleotide Therapeutics, with revenue, gross margin, and global market share of Oligonucleotide Therapeutics from 2021 to 2026.
Chapter 3, the Oligonucleotide Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Oligonucleotide Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oligonucleotide Therapeutics.
Chapter 13, to describe Oligonucleotide Therapeutics research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Oligonucleotide Therapeutics by Type
1.3.1 Overview: Global Oligonucleotide Therapeutics Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Oligonucleotide Therapeutics Consumption Value Market Share by Type in 2025
1.3.3 Antisense Oligonucleotides (ASO)
1.3.4 siRNA
1.3.5 mRNA
1.4 Global Oligonucleotide Therapeutics Market by Application
1.4.1 Overview: Global Oligonucleotide Therapeutics Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Neuromuscular Diseases
1.4.3 hATTR
1.4.4 COVID-19
1.4.5 Other
1.5 Global Oligonucleotide Therapeutics Market Size & Forecast
1.6 Global Oligonucleotide Therapeutics Market Size and Forecast by Region
1.6.1 Global Oligonucleotide Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Oligonucleotide Therapeutics Market Size by Region, (2021-2032)
1.6.3 North America Oligonucleotide Therapeutics Market Size and Prospect (2021-2032)
1.6.4 Europe Oligonucleotide Therapeutics Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Oligonucleotide Therapeutics Market Size and Prospect (2021-2032)
1.6.6 South America Oligonucleotide Therapeutics Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Oligonucleotide Therapeutics Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Sarepta Therapeutics
2.1.1 Sarepta Therapeutics Details
2.1.2 Sarepta Therapeutics Major Business
2.1.3 Sarepta Therapeutics Oligonucleotide Therapeutics Product and Solutions
2.1.4 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
2.2 Ionis Pharmaceuticals
2.2.1 Ionis Pharmaceuticals Details
2.2.2 Ionis Pharmaceuticals Major Business
2.2.3 Ionis Pharmaceuticals Oligonucleotide Therapeutics Product and Solutions
2.2.4 Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Ionis Pharmaceuticals Recent Developments and Future Plans
2.3 Alnylam
2.3.1 Alnylam Details
2.3.2 Alnylam Major Business
2.3.3 Alnylam Oligonucleotide Therapeutics Product and Solutions
2.3.4 Alnylam Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Alnylam Recent Developments and Future Plans
2.4 Biogen
2.4.1 Biogen Details
2.4.2 Biogen Major Business
2.4.3 Biogen Oligonucleotide Therapeutics Product and Solutions
2.4.4 Biogen Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Biogen Recent Developments and Future Plans
2.5 Nippon Shinyaku
2.5.1 Nippon Shinyaku Details
2.5.2 Nippon Shinyaku Major Business
2.5.3 Nippon Shinyaku Oligonucleotide Therapeutics Product and Solutions
2.5.4 Nippon Shinyaku Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Nippon Shinyaku Recent Developments and Future Plans
2.6 Sobi
2.6.1 Sobi Details
2.6.2 Sobi Major Business
2.6.3 Sobi Oligonucleotide Therapeutics Product and Solutions
2.6.4 Sobi Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Sobi Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Oligonucleotide Therapeutics Product and Solutions
2.7.4 Novartis Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Novartis Recent Developments and Future Plans
2.8 BioNTech
2.8.1 BioNTech Details
2.8.2 BioNTech Major Business
2.8.3 BioNTech Oligonucleotide Therapeutics Product and Solutions
2.8.4 BioNTech Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 BioNTech Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Oligonucleotide Therapeutics Product and Solutions
2.9.4 Pfizer Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 Moderna Therapeutics
2.10.1 Moderna Therapeutics Details
2.10.2 Moderna Therapeutics Major Business
2.10.3 Moderna Therapeutics Oligonucleotide Therapeutics Product and Solutions
2.10.4 Moderna Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Moderna Therapeutics Recent Developments and Future Plans
2.11 Jazz Pharmaceuticals
2.11.1 Jazz Pharmaceuticals Details
2.11.2 Jazz Pharmaceuticals Major Business
2.11.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Product and Solutions
2.11.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Jazz Pharmaceuticals Recent Developments and Future Plans
2.12 CureVac
2.12.1 CureVac Details
2.12.2 CureVac Major Business
2.12.3 CureVac Oligonucleotide Therapeutics Product and Solutions
2.12.4 CureVac Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 CureVac Recent Developments and Future Plans
2.13 Regulus Therapeutics
2.13.1 Regulus Therapeutics Details
2.13.2 Regulus Therapeutics Major Business
2.13.3 Regulus Therapeutics Oligonucleotide Therapeutics Product and Solutions
2.13.4 Regulus Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Regulus Therapeutics Recent Developments and Future Plans
2.14 ProQR
2.14.1 ProQR Details
2.14.2 ProQR Major Business
2.14.3 ProQR Oligonucleotide Therapeutics Product and Solutions
2.14.4 ProQR Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 ProQR Recent Developments and Future Plans
2.15 Secarna
2.15.1 Secarna Details
2.15.2 Secarna Major Business
2.15.3 Secarna Oligonucleotide Therapeutics Product and Solutions
2.15.4 Secarna Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Secarna Recent Developments and Future Plans
2.16 MiNA Therapeutics
2.16.1 MiNA Therapeutics Details
2.16.2 MiNA Therapeutics Major Business
2.16.3 MiNA Therapeutics Oligonucleotide Therapeutics Product and Solutions
2.16.4 MiNA Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 MiNA Therapeutics Recent Developments and Future Plans
2.17 Sylentis
2.17.1 Sylentis Details
2.17.2 Sylentis Major Business
2.17.3 Sylentis Oligonucleotide Therapeutics Product and Solutions
2.17.4 Sylentis Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Sylentis Recent Developments and Future Plans
2.18 Arrowhead
2.18.1 Arrowhead Details
2.18.2 Arrowhead Major Business
2.18.3 Arrowhead Oligonucleotide Therapeutics Product and Solutions
2.18.4 Arrowhead Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Arrowhead Recent Developments and Future Plans
2.19 Silence Therapeutics
2.19.1 Silence Therapeutics Details
2.19.2 Silence Therapeutics Major Business
2.19.3 Silence Therapeutics Oligonucleotide Therapeutics Product and Solutions
2.19.4 Silence Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 Silence Therapeutics Recent Developments and Future Plans
2.20 Dicerna
2.20.1 Dicerna Details
2.20.2 Dicerna Major Business
2.20.3 Dicerna Oligonucleotide Therapeutics Product and Solutions
2.20.4 Dicerna Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 Dicerna Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Oligonucleotide Therapeutics Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Oligonucleotide Therapeutics by Company Revenue
3.2.2 Top 3 Oligonucleotide Therapeutics Players Market Share in 2025
3.2.3 Top 6 Oligonucleotide Therapeutics Players Market Share in 2025
3.3 Oligonucleotide Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Oligonucleotide Therapeutics Market: Region Footprint
3.3.2 Oligonucleotide Therapeutics Market: Company Product Type Footprint
3.3.3 Oligonucleotide Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Oligonucleotide Therapeutics Consumption Value and Market Share by Type (2021-2026)
4.2 Global Oligonucleotide Therapeutics Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2026)
5.2 Global Oligonucleotide Therapeutics Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Oligonucleotide Therapeutics Consumption Value by Type (2021-2032)
6.2 North America Oligonucleotide Therapeutics Market Size by Application (2021-2032)
6.3 North America Oligonucleotide Therapeutics Market Size by Country
6.3.1 North America Oligonucleotide Therapeutics Consumption Value by Country (2021-2032)
6.3.2 United States Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
6.3.3 Canada Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
6.3.4 Mexico Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Oligonucleotide Therapeutics Consumption Value by Type (2021-2032)
7.2 Europe Oligonucleotide Therapeutics Consumption Value by Application (2021-2032)
7.3 Europe Oligonucleotide Therapeutics Market Size by Country
7.3.1 Europe Oligonucleotide Therapeutics Consumption Value by Country (2021-2032)
7.3.2 Germany Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
7.3.3 France Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
7.3.5 Russia Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
7.3.6 Italy Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region
8.3.1 Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Region (2021-2032)
8.3.2 China Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8.3.3 Japan Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8.3.4 South Korea Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8.3.5 India Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8.3.7 Australia Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Oligonucleotide Therapeutics Consumption Value by Type (2021-2032)
9.2 South America Oligonucleotide Therapeutics Consumption Value by Application (2021-2032)
9.3 South America Oligonucleotide Therapeutics Market Size by Country
9.3.1 South America Oligonucleotide Therapeutics Consumption Value by Country (2021-2032)
9.3.2 Brazil Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
9.3.3 Argentina Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country
10.3.1 Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Country (2021-2032)
10.3.2 Turkey Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
10.3.4 UAE Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Oligonucleotide Therapeutics Market Drivers
11.2 Oligonucleotide Therapeutics Market Restraints
11.3 Oligonucleotide Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Oligonucleotide Therapeutics Industry Chain
12.2 Oligonucleotide Therapeutics Upstream Analysis
12.3 Oligonucleotide Therapeutics Midstream Analysis
12.4 Oligonucleotide Therapeutics Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Oligonucleotide Therapeutics by Type
1.3.1 Overview: Global Oligonucleotide Therapeutics Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Oligonucleotide Therapeutics Consumption Value Market Share by Type in 2025
1.3.3 Antisense Oligonucleotides (ASO)
1.3.4 siRNA
1.3.5 mRNA
1.4 Global Oligonucleotide Therapeutics Market by Application
1.4.1 Overview: Global Oligonucleotide Therapeutics Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Neuromuscular Diseases
1.4.3 hATTR
1.4.4 COVID-19
1.4.5 Other
1.5 Global Oligonucleotide Therapeutics Market Size & Forecast
1.6 Global Oligonucleotide Therapeutics Market Size and Forecast by Region
1.6.1 Global Oligonucleotide Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Oligonucleotide Therapeutics Market Size by Region, (2021-2032)
1.6.3 North America Oligonucleotide Therapeutics Market Size and Prospect (2021-2032)
1.6.4 Europe Oligonucleotide Therapeutics Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Oligonucleotide Therapeutics Market Size and Prospect (2021-2032)
1.6.6 South America Oligonucleotide Therapeutics Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Oligonucleotide Therapeutics Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Sarepta Therapeutics
2.1.1 Sarepta Therapeutics Details
2.1.2 Sarepta Therapeutics Major Business
2.1.3 Sarepta Therapeutics Oligonucleotide Therapeutics Product and Solutions
2.1.4 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
2.2 Ionis Pharmaceuticals
2.2.1 Ionis Pharmaceuticals Details
2.2.2 Ionis Pharmaceuticals Major Business
2.2.3 Ionis Pharmaceuticals Oligonucleotide Therapeutics Product and Solutions
2.2.4 Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Ionis Pharmaceuticals Recent Developments and Future Plans
2.3 Alnylam
2.3.1 Alnylam Details
2.3.2 Alnylam Major Business
2.3.3 Alnylam Oligonucleotide Therapeutics Product and Solutions
2.3.4 Alnylam Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Alnylam Recent Developments and Future Plans
2.4 Biogen
2.4.1 Biogen Details
2.4.2 Biogen Major Business
2.4.3 Biogen Oligonucleotide Therapeutics Product and Solutions
2.4.4 Biogen Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Biogen Recent Developments and Future Plans
2.5 Nippon Shinyaku
2.5.1 Nippon Shinyaku Details
2.5.2 Nippon Shinyaku Major Business
2.5.3 Nippon Shinyaku Oligonucleotide Therapeutics Product and Solutions
2.5.4 Nippon Shinyaku Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Nippon Shinyaku Recent Developments and Future Plans
2.6 Sobi
2.6.1 Sobi Details
2.6.2 Sobi Major Business
2.6.3 Sobi Oligonucleotide Therapeutics Product and Solutions
2.6.4 Sobi Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Sobi Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Oligonucleotide Therapeutics Product and Solutions
2.7.4 Novartis Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Novartis Recent Developments and Future Plans
2.8 BioNTech
2.8.1 BioNTech Details
2.8.2 BioNTech Major Business
2.8.3 BioNTech Oligonucleotide Therapeutics Product and Solutions
2.8.4 BioNTech Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 BioNTech Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Oligonucleotide Therapeutics Product and Solutions
2.9.4 Pfizer Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 Moderna Therapeutics
2.10.1 Moderna Therapeutics Details
2.10.2 Moderna Therapeutics Major Business
2.10.3 Moderna Therapeutics Oligonucleotide Therapeutics Product and Solutions
2.10.4 Moderna Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Moderna Therapeutics Recent Developments and Future Plans
2.11 Jazz Pharmaceuticals
2.11.1 Jazz Pharmaceuticals Details
2.11.2 Jazz Pharmaceuticals Major Business
2.11.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Product and Solutions
2.11.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Jazz Pharmaceuticals Recent Developments and Future Plans
2.12 CureVac
2.12.1 CureVac Details
2.12.2 CureVac Major Business
2.12.3 CureVac Oligonucleotide Therapeutics Product and Solutions
2.12.4 CureVac Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 CureVac Recent Developments and Future Plans
2.13 Regulus Therapeutics
2.13.1 Regulus Therapeutics Details
2.13.2 Regulus Therapeutics Major Business
2.13.3 Regulus Therapeutics Oligonucleotide Therapeutics Product and Solutions
2.13.4 Regulus Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Regulus Therapeutics Recent Developments and Future Plans
2.14 ProQR
2.14.1 ProQR Details
2.14.2 ProQR Major Business
2.14.3 ProQR Oligonucleotide Therapeutics Product and Solutions
2.14.4 ProQR Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 ProQR Recent Developments and Future Plans
2.15 Secarna
2.15.1 Secarna Details
2.15.2 Secarna Major Business
2.15.3 Secarna Oligonucleotide Therapeutics Product and Solutions
2.15.4 Secarna Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Secarna Recent Developments and Future Plans
2.16 MiNA Therapeutics
2.16.1 MiNA Therapeutics Details
2.16.2 MiNA Therapeutics Major Business
2.16.3 MiNA Therapeutics Oligonucleotide Therapeutics Product and Solutions
2.16.4 MiNA Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 MiNA Therapeutics Recent Developments and Future Plans
2.17 Sylentis
2.17.1 Sylentis Details
2.17.2 Sylentis Major Business
2.17.3 Sylentis Oligonucleotide Therapeutics Product and Solutions
2.17.4 Sylentis Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Sylentis Recent Developments and Future Plans
2.18 Arrowhead
2.18.1 Arrowhead Details
2.18.2 Arrowhead Major Business
2.18.3 Arrowhead Oligonucleotide Therapeutics Product and Solutions
2.18.4 Arrowhead Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Arrowhead Recent Developments and Future Plans
2.19 Silence Therapeutics
2.19.1 Silence Therapeutics Details
2.19.2 Silence Therapeutics Major Business
2.19.3 Silence Therapeutics Oligonucleotide Therapeutics Product and Solutions
2.19.4 Silence Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 Silence Therapeutics Recent Developments and Future Plans
2.20 Dicerna
2.20.1 Dicerna Details
2.20.2 Dicerna Major Business
2.20.3 Dicerna Oligonucleotide Therapeutics Product and Solutions
2.20.4 Dicerna Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 Dicerna Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Oligonucleotide Therapeutics Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Oligonucleotide Therapeutics by Company Revenue
3.2.2 Top 3 Oligonucleotide Therapeutics Players Market Share in 2025
3.2.3 Top 6 Oligonucleotide Therapeutics Players Market Share in 2025
3.3 Oligonucleotide Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Oligonucleotide Therapeutics Market: Region Footprint
3.3.2 Oligonucleotide Therapeutics Market: Company Product Type Footprint
3.3.3 Oligonucleotide Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Oligonucleotide Therapeutics Consumption Value and Market Share by Type (2021-2026)
4.2 Global Oligonucleotide Therapeutics Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2026)
5.2 Global Oligonucleotide Therapeutics Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Oligonucleotide Therapeutics Consumption Value by Type (2021-2032)
6.2 North America Oligonucleotide Therapeutics Market Size by Application (2021-2032)
6.3 North America Oligonucleotide Therapeutics Market Size by Country
6.3.1 North America Oligonucleotide Therapeutics Consumption Value by Country (2021-2032)
6.3.2 United States Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
6.3.3 Canada Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
6.3.4 Mexico Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Oligonucleotide Therapeutics Consumption Value by Type (2021-2032)
7.2 Europe Oligonucleotide Therapeutics Consumption Value by Application (2021-2032)
7.3 Europe Oligonucleotide Therapeutics Market Size by Country
7.3.1 Europe Oligonucleotide Therapeutics Consumption Value by Country (2021-2032)
7.3.2 Germany Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
7.3.3 France Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
7.3.5 Russia Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
7.3.6 Italy Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region
8.3.1 Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Region (2021-2032)
8.3.2 China Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8.3.3 Japan Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8.3.4 South Korea Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8.3.5 India Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
8.3.7 Australia Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Oligonucleotide Therapeutics Consumption Value by Type (2021-2032)
9.2 South America Oligonucleotide Therapeutics Consumption Value by Application (2021-2032)
9.3 South America Oligonucleotide Therapeutics Market Size by Country
9.3.1 South America Oligonucleotide Therapeutics Consumption Value by Country (2021-2032)
9.3.2 Brazil Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
9.3.3 Argentina Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country
10.3.1 Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Country (2021-2032)
10.3.2 Turkey Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
10.3.4 UAE Oligonucleotide Therapeutics Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Oligonucleotide Therapeutics Market Drivers
11.2 Oligonucleotide Therapeutics Market Restraints
11.3 Oligonucleotide Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Oligonucleotide Therapeutics Industry Chain
12.2 Oligonucleotide Therapeutics Upstream Analysis
12.3 Oligonucleotide Therapeutics Midstream Analysis
12.4 Oligonucleotide Therapeutics Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF FIGURES
Table 1. Global Oligonucleotide Therapeutics Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Oligonucleotide Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Oligonucleotide Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Oligonucleotide Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Sarepta Therapeutics Major Business
Table 7. Sarepta Therapeutics Oligonucleotide Therapeutics Product and Solutions
Table 8. Sarepta Therapeutics Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Sarepta Therapeutics Recent Developments and Future Plans
Table 10. Ionis Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Ionis Pharmaceuticals Major Business
Table 12. Ionis Pharmaceuticals Oligonucleotide Therapeutics Product and Solutions
Table 13. Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Ionis Pharmaceuticals Recent Developments and Future Plans
Table 15. Alnylam Company Information, Head Office, and Major Competitors
Table 16. Alnylam Major Business
Table 17. Alnylam Oligonucleotide Therapeutics Product and Solutions
Table 18. Alnylam Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Biogen Company Information, Head Office, and Major Competitors
Table 20. Biogen Major Business
Table 21. Biogen Oligonucleotide Therapeutics Product and Solutions
Table 22. Biogen Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Biogen Recent Developments and Future Plans
Table 24. Nippon Shinyaku Company Information, Head Office, and Major Competitors
Table 25. Nippon Shinyaku Major Business
Table 26. Nippon Shinyaku Oligonucleotide Therapeutics Product and Solutions
Table 27. Nippon Shinyaku Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Nippon Shinyaku Recent Developments and Future Plans
Table 29. Sobi Company Information, Head Office, and Major Competitors
Table 30. Sobi Major Business
Table 31. Sobi Oligonucleotide Therapeutics Product and Solutions
Table 32. Sobi Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Sobi Recent Developments and Future Plans
Table 34. Novartis Company Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Oligonucleotide Therapeutics Product and Solutions
Table 37. Novartis Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Novartis Recent Developments and Future Plans
Table 39. BioNTech Company Information, Head Office, and Major Competitors
Table 40. BioNTech Major Business
Table 41. BioNTech Oligonucleotide Therapeutics Product and Solutions
Table 42. BioNTech Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. BioNTech Recent Developments and Future Plans
Table 44. Pfizer Company Information, Head Office, and Major Competitors
Table 45. Pfizer Major Business
Table 46. Pfizer Oligonucleotide Therapeutics Product and Solutions
Table 47. Pfizer Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Pfizer Recent Developments and Future Plans
Table 49. Moderna Therapeutics Company Information, Head Office, and Major Competitors
Table 50. Moderna Therapeutics Major Business
Table 51. Moderna Therapeutics Oligonucleotide Therapeutics Product and Solutions
Table 52. Moderna Therapeutics Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. Moderna Therapeutics Recent Developments and Future Plans
Table 54. Jazz Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 55. Jazz Pharmaceuticals Major Business
Table 56. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product and Solutions
Table 57. Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Jazz Pharmaceuticals Recent Developments and Future Plans
Table 59. CureVac Company Information, Head Office, and Major Competitors
Table 60. CureVac Major Business
Table 61. CureVac Oligonucleotide Therapeutics Product and Solutions
Table 62. CureVac Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 63. CureVac Recent Developments and Future Plans
Table 64. Regulus Therapeutics Company Information, Head Office, and Major Competitors
Table 65. Regulus Therapeutics Major Business
Table 66. Regulus Therapeutics Oligonucleotide Therapeutics Product and Solutions
Table 67. Regulus Therapeutics Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 68. Regulus Therapeutics Recent Developments and Future Plans
Table 69. ProQR Company Information, Head Office, and Major Competitors
Table 70. ProQR Major Business
Table 71. ProQR Oligonucleotide Therapeutics Product and Solutions
Table 72. ProQR Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 73. ProQR Recent Developments and Future Plans
Table 74. Secarna Company Information, Head Office, and Major Competitors
Table 75. Secarna Major Business
Table 76. Secarna Oligonucleotide Therapeutics Product and Solutions
Table 77. Secarna Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. Secarna Recent Developments and Future Plans
Table 79. MiNA Therapeutics Company Information, Head Office, and Major Competitors
Table 80. MiNA Therapeutics Major Business
Table 81. MiNA Therapeutics Oligonucleotide Therapeutics Product and Solutions
Table 82. MiNA Therapeutics Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 83. MiNA Therapeutics Recent Developments and Future Plans
Table 84. Sylentis Company Information, Head Office, and Major Competitors
Table 85. Sylentis Major Business
Table 86. Sylentis Oligonucleotide Therapeutics Product and Solutions
Table 87. Sylentis Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 88. Sylentis Recent Developments and Future Plans
Table 89. Arrowhead Company Information, Head Office, and Major Competitors
Table 90. Arrowhead Major Business
Table 91. Arrowhead Oligonucleotide Therapeutics Product and Solutions
Table 92. Arrowhead Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 93. Arrowhead Recent Developments and Future Plans
Table 94. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 95. Silence Therapeutics Major Business
Table 96. Silence Therapeutics Oligonucleotide Therapeutics Product and Solutions
Table 97. Silence Therapeutics Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 98. Silence Therapeutics Recent Developments and Future Plans
Table 99. Dicerna Company Information, Head Office, and Major Competitors
Table 100. Dicerna Major Business
Table 101. Dicerna Oligonucleotide Therapeutics Product and Solutions
Table 102. Dicerna Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Dicerna Recent Developments and Future Plans
Table 104. Global Oligonucleotide Therapeutics Revenue (USD Million) by Players (2021-2026)
Table 105. Global Oligonucleotide Therapeutics Revenue Share by Players (2021-2026)
Table 106. Breakdown of Oligonucleotide Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 107. Market Position of Players in Oligonucleotide Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 108. Head Office of Key Oligonucleotide Therapeutics Players
Table 109. Oligonucleotide Therapeutics Market: Company Product Type Footprint
Table 110. Oligonucleotide Therapeutics Market: Company Product Application Footprint
Table 111. Oligonucleotide Therapeutics New Market Entrants and Barriers to Market Entry
Table 112. Oligonucleotide Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 113. Global Oligonucleotide Therapeutics Consumption Value (USD Million) by Type (2021-2026)
Table 114. Global Oligonucleotide Therapeutics Consumption Value Share by Type (2021-2026)
Table 115. Global Oligonucleotide Therapeutics Consumption Value Forecast by Type (2027-2032)
Table 116. Global Oligonucleotide Therapeutics Consumption Value by Application (2021-2026)
Table 117. Global Oligonucleotide Therapeutics Consumption Value Forecast by Application (2027-2032)
Table 118. North America Oligonucleotide Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 119. North America Oligonucleotide Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 120. North America Oligonucleotide Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 121. North America Oligonucleotide Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 122. North America Oligonucleotide Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 123. North America Oligonucleotide Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 124. Europe Oligonucleotide Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 125. Europe Oligonucleotide Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 126. Europe Oligonucleotide Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 127. Europe Oligonucleotide Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 128. Europe Oligonucleotide Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 129. Europe Oligonucleotide Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 130. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 131. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 132. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 133. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 134. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 135. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 136. South America Oligonucleotide Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 137. South America Oligonucleotide Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 138. South America Oligonucleotide Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 139. South America Oligonucleotide Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 140. South America Oligonucleotide Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 141. South America Oligonucleotide Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 142. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 143. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 144. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 145. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 146. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 147. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 148. Global Key Players of Oligonucleotide Therapeutics Upstream (Raw Materials)
Table 149. Global Oligonucleotide Therapeutics Typical Customers
LIST OF FIGURES
Figure 1. Oligonucleotide Therapeutics Picture
Figure 2. Global Oligonucleotide Therapeutics Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Oligonucleotide Therapeutics Consumption Value Market Share by Type in 2025
Figure 4. Antisense Oligonucleotides (ASO)
Figure 5. siRNA
Figure 6. mRNA
Figure 7. Global Oligonucleotide Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. Oligonucleotide Therapeutics Consumption Value Market Share by Application in 2025
Figure 9. Neuromuscular Diseases Picture
Figure 10. hATTR Picture
Figure 11. COVID-19 Picture
Figure 12. Other Picture
Figure 13. Global Oligonucleotide Therapeutics Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 14. Global Oligonucleotide Therapeutics Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 15. Global Market Oligonucleotide Therapeutics Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 16. Global Oligonucleotide Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 17. Global Oligonucleotide Therapeutics Consumption Value Market Share by Region in 2025
Figure 18. North America Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 20. Asia-Pacific Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 21. South America Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 22. Middle East & Africa Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global Oligonucleotide Therapeutics Revenue Share by Players in 2025
Figure 25. Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 26. Market Share of Oligonucleotide Therapeutics by Player Revenue in 2025
Figure 27. Top 3 Oligonucleotide Therapeutics Players Market Share in 2025
Figure 28. Top 6 Oligonucleotide Therapeutics Players Market Share in 2025
Figure 29. Global Oligonucleotide Therapeutics Consumption Value Share by Type (2021-2026)
Figure 30. Global Oligonucleotide Therapeutics Market Share Forecast by Type (2027-2032)
Figure 31. Global Oligonucleotide Therapeutics Consumption Value Share by Application (2021-2026)
Figure 32. Global Oligonucleotide Therapeutics Market Share Forecast by Application (2027-2032)
Figure 33. North America Oligonucleotide Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 34. North America Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 35. North America Oligonucleotide Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 36. United States Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 37. Canada Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 38. Mexico Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 39. Europe Oligonucleotide Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 40. Europe Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 41. Europe Oligonucleotide Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 42. Germany Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 43. France Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 44. United Kingdom Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 45. Russia Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 46. Italy Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 47. Asia-Pacific Oligonucleotide Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 48. Asia-Pacific Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 49. Asia-Pacific Oligonucleotide Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 50. China Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 51. Japan Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 52. South Korea Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 53. India Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 54. Southeast Asia Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 55. Australia Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 56. South America Oligonucleotide Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 57. South America Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 58. South America Oligonucleotide Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 59. Brazil Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 60. Argentina Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 61. Middle East & Africa Oligonucleotide Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 62. Middle East & Africa Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 63. Middle East & Africa Oligonucleotide Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 64. Turkey Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 65. Saudi Arabia Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 66. UAE Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 67. Oligonucleotide Therapeutics Market Drivers
Figure 68. Oligonucleotide Therapeutics Market Restraints
Figure 69. Oligonucleotide Therapeutics Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Oligonucleotide Therapeutics Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Table 1. Global Oligonucleotide Therapeutics Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Oligonucleotide Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Oligonucleotide Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Oligonucleotide Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Sarepta Therapeutics Major Business
Table 7. Sarepta Therapeutics Oligonucleotide Therapeutics Product and Solutions
Table 8. Sarepta Therapeutics Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Sarepta Therapeutics Recent Developments and Future Plans
Table 10. Ionis Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Ionis Pharmaceuticals Major Business
Table 12. Ionis Pharmaceuticals Oligonucleotide Therapeutics Product and Solutions
Table 13. Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Ionis Pharmaceuticals Recent Developments and Future Plans
Table 15. Alnylam Company Information, Head Office, and Major Competitors
Table 16. Alnylam Major Business
Table 17. Alnylam Oligonucleotide Therapeutics Product and Solutions
Table 18. Alnylam Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Biogen Company Information, Head Office, and Major Competitors
Table 20. Biogen Major Business
Table 21. Biogen Oligonucleotide Therapeutics Product and Solutions
Table 22. Biogen Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Biogen Recent Developments and Future Plans
Table 24. Nippon Shinyaku Company Information, Head Office, and Major Competitors
Table 25. Nippon Shinyaku Major Business
Table 26. Nippon Shinyaku Oligonucleotide Therapeutics Product and Solutions
Table 27. Nippon Shinyaku Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Nippon Shinyaku Recent Developments and Future Plans
Table 29. Sobi Company Information, Head Office, and Major Competitors
Table 30. Sobi Major Business
Table 31. Sobi Oligonucleotide Therapeutics Product and Solutions
Table 32. Sobi Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Sobi Recent Developments and Future Plans
Table 34. Novartis Company Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Oligonucleotide Therapeutics Product and Solutions
Table 37. Novartis Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Novartis Recent Developments and Future Plans
Table 39. BioNTech Company Information, Head Office, and Major Competitors
Table 40. BioNTech Major Business
Table 41. BioNTech Oligonucleotide Therapeutics Product and Solutions
Table 42. BioNTech Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. BioNTech Recent Developments and Future Plans
Table 44. Pfizer Company Information, Head Office, and Major Competitors
Table 45. Pfizer Major Business
Table 46. Pfizer Oligonucleotide Therapeutics Product and Solutions
Table 47. Pfizer Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Pfizer Recent Developments and Future Plans
Table 49. Moderna Therapeutics Company Information, Head Office, and Major Competitors
Table 50. Moderna Therapeutics Major Business
Table 51. Moderna Therapeutics Oligonucleotide Therapeutics Product and Solutions
Table 52. Moderna Therapeutics Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. Moderna Therapeutics Recent Developments and Future Plans
Table 54. Jazz Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 55. Jazz Pharmaceuticals Major Business
Table 56. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product and Solutions
Table 57. Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Jazz Pharmaceuticals Recent Developments and Future Plans
Table 59. CureVac Company Information, Head Office, and Major Competitors
Table 60. CureVac Major Business
Table 61. CureVac Oligonucleotide Therapeutics Product and Solutions
Table 62. CureVac Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 63. CureVac Recent Developments and Future Plans
Table 64. Regulus Therapeutics Company Information, Head Office, and Major Competitors
Table 65. Regulus Therapeutics Major Business
Table 66. Regulus Therapeutics Oligonucleotide Therapeutics Product and Solutions
Table 67. Regulus Therapeutics Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 68. Regulus Therapeutics Recent Developments and Future Plans
Table 69. ProQR Company Information, Head Office, and Major Competitors
Table 70. ProQR Major Business
Table 71. ProQR Oligonucleotide Therapeutics Product and Solutions
Table 72. ProQR Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 73. ProQR Recent Developments and Future Plans
Table 74. Secarna Company Information, Head Office, and Major Competitors
Table 75. Secarna Major Business
Table 76. Secarna Oligonucleotide Therapeutics Product and Solutions
Table 77. Secarna Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. Secarna Recent Developments and Future Plans
Table 79. MiNA Therapeutics Company Information, Head Office, and Major Competitors
Table 80. MiNA Therapeutics Major Business
Table 81. MiNA Therapeutics Oligonucleotide Therapeutics Product and Solutions
Table 82. MiNA Therapeutics Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 83. MiNA Therapeutics Recent Developments and Future Plans
Table 84. Sylentis Company Information, Head Office, and Major Competitors
Table 85. Sylentis Major Business
Table 86. Sylentis Oligonucleotide Therapeutics Product and Solutions
Table 87. Sylentis Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 88. Sylentis Recent Developments and Future Plans
Table 89. Arrowhead Company Information, Head Office, and Major Competitors
Table 90. Arrowhead Major Business
Table 91. Arrowhead Oligonucleotide Therapeutics Product and Solutions
Table 92. Arrowhead Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 93. Arrowhead Recent Developments and Future Plans
Table 94. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 95. Silence Therapeutics Major Business
Table 96. Silence Therapeutics Oligonucleotide Therapeutics Product and Solutions
Table 97. Silence Therapeutics Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 98. Silence Therapeutics Recent Developments and Future Plans
Table 99. Dicerna Company Information, Head Office, and Major Competitors
Table 100. Dicerna Major Business
Table 101. Dicerna Oligonucleotide Therapeutics Product and Solutions
Table 102. Dicerna Oligonucleotide Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Dicerna Recent Developments and Future Plans
Table 104. Global Oligonucleotide Therapeutics Revenue (USD Million) by Players (2021-2026)
Table 105. Global Oligonucleotide Therapeutics Revenue Share by Players (2021-2026)
Table 106. Breakdown of Oligonucleotide Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 107. Market Position of Players in Oligonucleotide Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 108. Head Office of Key Oligonucleotide Therapeutics Players
Table 109. Oligonucleotide Therapeutics Market: Company Product Type Footprint
Table 110. Oligonucleotide Therapeutics Market: Company Product Application Footprint
Table 111. Oligonucleotide Therapeutics New Market Entrants and Barriers to Market Entry
Table 112. Oligonucleotide Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 113. Global Oligonucleotide Therapeutics Consumption Value (USD Million) by Type (2021-2026)
Table 114. Global Oligonucleotide Therapeutics Consumption Value Share by Type (2021-2026)
Table 115. Global Oligonucleotide Therapeutics Consumption Value Forecast by Type (2027-2032)
Table 116. Global Oligonucleotide Therapeutics Consumption Value by Application (2021-2026)
Table 117. Global Oligonucleotide Therapeutics Consumption Value Forecast by Application (2027-2032)
Table 118. North America Oligonucleotide Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 119. North America Oligonucleotide Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 120. North America Oligonucleotide Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 121. North America Oligonucleotide Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 122. North America Oligonucleotide Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 123. North America Oligonucleotide Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 124. Europe Oligonucleotide Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 125. Europe Oligonucleotide Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 126. Europe Oligonucleotide Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 127. Europe Oligonucleotide Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 128. Europe Oligonucleotide Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 129. Europe Oligonucleotide Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 130. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 131. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 132. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 133. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 134. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 135. Asia-Pacific Oligonucleotide Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 136. South America Oligonucleotide Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 137. South America Oligonucleotide Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 138. South America Oligonucleotide Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 139. South America Oligonucleotide Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 140. South America Oligonucleotide Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 141. South America Oligonucleotide Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 142. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 143. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 144. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 145. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 146. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 147. Middle East & Africa Oligonucleotide Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 148. Global Key Players of Oligonucleotide Therapeutics Upstream (Raw Materials)
Table 149. Global Oligonucleotide Therapeutics Typical Customers
LIST OF FIGURES
Figure 1. Oligonucleotide Therapeutics Picture
Figure 2. Global Oligonucleotide Therapeutics Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Oligonucleotide Therapeutics Consumption Value Market Share by Type in 2025
Figure 4. Antisense Oligonucleotides (ASO)
Figure 5. siRNA
Figure 6. mRNA
Figure 7. Global Oligonucleotide Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. Oligonucleotide Therapeutics Consumption Value Market Share by Application in 2025
Figure 9. Neuromuscular Diseases Picture
Figure 10. hATTR Picture
Figure 11. COVID-19 Picture
Figure 12. Other Picture
Figure 13. Global Oligonucleotide Therapeutics Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 14. Global Oligonucleotide Therapeutics Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 15. Global Market Oligonucleotide Therapeutics Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 16. Global Oligonucleotide Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 17. Global Oligonucleotide Therapeutics Consumption Value Market Share by Region in 2025
Figure 18. North America Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 20. Asia-Pacific Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 21. South America Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 22. Middle East & Africa Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global Oligonucleotide Therapeutics Revenue Share by Players in 2025
Figure 25. Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 26. Market Share of Oligonucleotide Therapeutics by Player Revenue in 2025
Figure 27. Top 3 Oligonucleotide Therapeutics Players Market Share in 2025
Figure 28. Top 6 Oligonucleotide Therapeutics Players Market Share in 2025
Figure 29. Global Oligonucleotide Therapeutics Consumption Value Share by Type (2021-2026)
Figure 30. Global Oligonucleotide Therapeutics Market Share Forecast by Type (2027-2032)
Figure 31. Global Oligonucleotide Therapeutics Consumption Value Share by Application (2021-2026)
Figure 32. Global Oligonucleotide Therapeutics Market Share Forecast by Application (2027-2032)
Figure 33. North America Oligonucleotide Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 34. North America Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 35. North America Oligonucleotide Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 36. United States Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 37. Canada Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 38. Mexico Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 39. Europe Oligonucleotide Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 40. Europe Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 41. Europe Oligonucleotide Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 42. Germany Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 43. France Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 44. United Kingdom Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 45. Russia Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 46. Italy Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 47. Asia-Pacific Oligonucleotide Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 48. Asia-Pacific Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 49. Asia-Pacific Oligonucleotide Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 50. China Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 51. Japan Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 52. South Korea Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 53. India Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 54. Southeast Asia Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 55. Australia Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 56. South America Oligonucleotide Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 57. South America Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 58. South America Oligonucleotide Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 59. Brazil Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 60. Argentina Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 61. Middle East & Africa Oligonucleotide Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 62. Middle East & Africa Oligonucleotide Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 63. Middle East & Africa Oligonucleotide Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 64. Turkey Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 65. Saudi Arabia Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 66. UAE Oligonucleotide Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 67. Oligonucleotide Therapeutics Market Drivers
Figure 68. Oligonucleotide Therapeutics Market Restraints
Figure 69. Oligonucleotide Therapeutics Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Oligonucleotide Therapeutics Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
